Abdom Radiol (NY)

1. ZHAO Z, Zhao Z, Bu X, Wang M, et al
   Added value of synthetic MRI in refining biparametric MRI VI-RADS for predicting muscle-invasive bladder cancer.
   Abdom Radiol (NY). 2026 Jan 19. doi: 10.1007/s00261-025-05365.
   

   >> Share

   
   
2. SUGAWARA D, Hatakeyama K, Konno M, Tozawa T, et al
   Decision tree models combining Bi-parametric vesical imaging reporting and data system and apparent diffusion coefficient metrics for predicting muscle-invasive bladder cancer.
   Abdom Radiol (NY). 2026 Jan 23. doi: 10.1007/s00261-026-05389.
   

   >> Share

   
   

   
   Acad Radiol

3. DOGRA S, Lee J, Siriruchatanon M, Gu Z, et al
   Incidental Bladder Lesions on Prostate Multiparametric MRI: Prevalence and Factors Associated with Bladder Carcinoma.
   Acad Radiol. 2026;33:472-481.
   

   >> Share

   
   

   
   ACS Appl Mater Interfaces

4. LIU L, Liang T, Huang G, Deng D, et al
   Electroacupuncture in Combination with Bevacizumab Hydrogel Provides a Therapeutic Strategy for Bladder Cancer.
   ACS Appl Mater Interfaces. 2026 Jan 22. doi: 10.1021/acsami.6c00404.
   

   >> Share

   
   

   
   Acta Biomater

5. CARVALHO D, Pinto S, Sarmento B
   Modeling the human bladder tissue using three dimensional in vitro approaches as a tool for drug screening platforms.
   Acta Biomater. 2026;210:296-313.
   

   >> Share

   
   

   
   Ann Surg Oncol

6. JIANG M, Chen S, Ma H, Shi Y, et al
   Intratumoral and Peritumoral Fat CT?Based Radiomics for Predicting Recurrence Risk in Non-Muscle-Invasive Bladder Cancer: A Two-Center Study.
   Ann Surg Oncol. 2026 Jan 20. doi: 10.1245/s10434-025-18981.
   

   >> Share

   
   

   
   Arch Sex Behav

7. CALOUDAS AB, Haltom TM, Taylor JM
   "It's Killed My Sex Life": Veteran Bladder Cancer Survivors' Perspectives on Sexual Problems and Intimacy.
   Arch Sex Behav. 2026 Jan 21. doi: 10.1007/s10508-025-03364.
   

   >> Share

   
   

   
   Asian Pac J Cancer Prev

8. DO NT, Nguyen Tung L, Nguyen Cong D, Do MT, et al
   Tumor Morphology as a Risk Factor for Muscle Invasiveness in Newly Diagnosed Bladder Cancer: A Stratified Analysis.
   Asian Pac J Cancer Prev. 2026;27:151-156.
   

   >> Share

   
   

   
   Biol Direct

9. CAI J, Jiao C, Xu Y, Zhang F, et al
   Polarity protein Par3 deficiency promotes metastasis of bladder cancer via interaction of Ppp1r12c.
   Biol Direct. 2026 Jan 20. doi: 10.1186/s13062-026-00727.
   

   >> Share

   
   

   
   BJU Int

10. ABOU CHAKRA M, McElree IM, Mott SL, O'Donnell MA, et al
    Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer.
    BJU Int. 2026 Jan 19. doi: 10.1111/bju.70149.
    

    >> Share

    
    
11. SILVANI C, Santangelo A, Considine J, Tylecki A, et al
    Area deprivation and cancer-specific mortality in non-muscle-invasive bladder cancer: a statewide analysis.
    BJU Int. 2026 Jan 20. doi: 10.1111/bju.70151.
    

    >> Share

    
    

    
    Bladder Cancer

12. KAUFMANN E, Aeppli S, Affentranger A, Arnold N, et al
    Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer.
    Bladder Cancer. 2026;12:23523735251410823.
    

    >> Share

    
    

    
    BMC Cancer

13. RAO XP, Zou XC, Yu ZJ, Yuan YY, et al
    Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer.
    BMC Cancer. 2026 Jan 19. doi: 10.1186/s12885-026-15554.
    

    >> Share

    
    

    
    Cancer Lett

14. HUANG Y, Chen C, Su M, Ye W, et al
    TMEM11 promotes cisplatin resistance by inhibiting BNIP3-mediated mitophagy in bladder cancer.
    Cancer Lett. 2026;641:218271.
    

    >> Share

    
    

    
    Cancer Treat Res Commun

15. RICHTERS A, Franken MD, Meijer RP, van der Heijden AG, et al
    Treatments and survival outcomes of patients with synchronous and metachronous metastatic bladder cancer: A population-based nationwide cohort study.
    Cancer Treat Res Commun. 2026;46:101099.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

16. REVERDY T, Izarn F, Allignet B, Roubaud G, et al
    Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study.
    Clin Genitourin Cancer. 2026;24:102465.
    

    >> Share

    
    
17. KURIAN M, Mamtani R, Elghawy O, Nimgaonkar V, et al
    Real-World Enfortumab Vedotin +/- Pembrolizumab Treatment-Based Toxicities and Associations With Survival in Advanced Urothelial Carcinoma.
    Clin Genitourin Cancer. 2026;24:102474.
    

    >> Share

    
    
18. RICCIARDI G, Tralongo P, Pierconti F, Zuccala V, et al
    Urothelial Carcinoma In Situ: Advances in Diagnosis and Management.
    Clin Genitourin Cancer. 2026;24:102478.
    

    >> Share

    
    

    
    Cureus

19. EL MJABBER R, Alami R, Aouzah F, Bezzari W, et al
    Integrated Boost vs. Sequential Scheme in Volumetric Modulated Arc Therapy (VMAT) for Trimodal Bladder Cancer Therapy: A Comparative Study.
    Cureus. 2025;17:e99438.
    

    >> Share

    
    

    
    Eur J Med Chem

20. SHANG LL, Hu TL, Xiong S, Xu S, et al
    Design and synthesis of dual-activity biphenyl inhibitors against SARS-CoV-2 and bladder cancer.
    Eur J Med Chem. 2026;306:118581.
    

    >> Share

    
    

    
    Eur Urol

21. KITAMURA H, Tsukamoto T, Kakehi Y, Mizusawa J, et al
    Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.
    Eur Urol. 2026 Jan 21:S0302-2838(26)00014-X. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
22. GARMAN TS, Kates MR
    Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
    Eur Urol. 2026 Jan 19:S0302-2838(26)00016-3. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
23. PICHLER R, Subiela JD, Scilipoti P, Rehder P, et al
    Regional Node-positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings.
    Eur Urol. 2026 Jan 19:S0302-2838(26)00019-9. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    
24. NAGUMO Y, Kimura T, Ishikawa H, Sekino Y, et al
    Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial.
    Eur Urol. 2026 Jan 17:S0302-2838(25)04872-9. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    

    
    Eur Urol Focus

25. GABRIEL PE, Xylinas E
    The Future of Non-muscle-invasive Bladder Cancer: Towards a Molecular-Digital Paradigm for Personalized Management.
    Eur Urol Focus. 2026 Jan 22:S2405-4569(26)00004.
    

    >> Share

    
    

    
    Eur Urol Oncol

26. MEZEPO G, Khene ZE, Boustani J, Kleinclauss F, et al
    Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study.
    Eur Urol Oncol. 2026 Jan 22:S2588-9311(25)00343.
    

    >> Share

    
    

    
    Front Immunol

27. NAGUMO Y, Ye X, Shi T, Mathis BJ, et al
    Revealing intra-group immunotherapy response heterogeneity in metastatic urothelial carcinoma through interpretable feature extraction and spectral clustering.
    Front Immunol. 2026;16:1629001.
    

    >> Share

    
    

    
    Front Oncol

28. LI M, Liu X, Xue Y, Lu Y, et al
    Integrative bulk and single-cell transcriptomic analysis reveals COL1A2-driven ECM remodeling and focal adhesion signaling associated with the transition from non-muscle-invasive to muscle-invasive bladder cancer.
    Front Oncol. 2026;15:1716324.
    

    >> Share

    
    
29. YAN B, Hu W, Li Y, Feng T, et al
    Hyperthermic intravesical chemotherapy with gemcitabine versus Bacillus Calmette-Guerin in intermediate- and high-risk non-muscle-invasive bladder cancer.
    Front Oncol. 2026;15:1715762.
    

    >> Share

    
    
30. SONG F, Su S, Zhang X, Cao Y, et al
    Association between the red cell distribution width-to-albumin ratio and recurrence-free survival and overall survival in patients with non-muscle-invasive bladder cancer: a retrospective cohort study.
    Front Oncol. 2026;15:1710047.
    

    >> Share

    
    

    
    Gan To Kagaku Ryoho

31. HAYAKAWA N, Kikuchi E
    [Current Landscape of Sequential Treatment Strategy in Metastatic Urothelial Carcinoma].
    Gan To Kagaku Ryoho. 2026;53:21-24.
    

    >> Share

    
    
32. KITA Y
    [Current Development of Perioperative Immune Checkpoint Inhibitor Therapy for Muscle-Invasive Bladder Cancer].
    Gan To Kagaku Ryoho. 2026;53:16-20.
    

    >> Share

    
    
33. SHIGEHISA R, Fukata S, Inoue K
    [Evolving Pharmacotherapy for Bladder Cancer-From Non-Muscle-Invasive to Metastatic Disease-Development of Novel Therapies for BCG-Unresponsive NMIBC].
    Gan To Kagaku Ryoho. 2026;53:10-15.
    

    >> Share

    
    
34. KAWAHARA T
    [Recent Progress in Novel Therapies for Non-Muscle Invasive Bladder Cancer].
    Gan To Kagaku Ryoho. 2026;53:7-9.
    

    >> Share

    
    

    
    Hypertens Res

35. YAMANAKA R, Miura K, Yamasaki N, Ogata S, et al
    Angiotensin II type 1 receptor signaling promotes bladder cancer progression and its inhibition by Losartan.
    Hypertens Res. 2026 Jan 19. doi: 10.1038/s41440-025-02535.
    

    >> Share

    
    

    
    Int Braz J Urol

36. REIS LO
    Bladder Cancer Immunotherapy in 2025: ALBAN, CREST, POTOMAC, and the Winner Is BCG!
    Int Braz J Urol. 2026;52:e20259921.
    

    >> Share

    
    

    
    Int Immunopharmacol

37. XU T, Wang K, Chen Y, Yu Y, et al
    Adjuvant bacillus Calmette-Guerin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naive high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study.
    Int Immunopharmacol. 2026;172:116186.
    

    >> Share

    
    

    
    Int J Mol Med

38. ZHAO Q, Gao S, Du Q, Liu Y, et al
    [Expression of Concern] Long non?coding RNA SNHG20 promotes bladder cancer via activating the Wnt/beta?catenin signalling pathway.
    Int J Mol Med. 2026;57:66.
    

    >> Share

    
    

    
    Int J Surg

39. SONG S MSC, Yang W MSc, Gao C MD
    Comment on "The role of adjuvant chemotherapy after radical surgery in patients with lymph node-positive bladder cancer or locally advanced (pT3, pT4a) bladder cancer: a meta-analysis and systematic review".
    Int J Surg. 2026 Jan 20. doi: 10.1097/JS9.0000000000004892.
    

    >> Share

    
    
40. 
    Long-term impact of synchronous and metachronous bladder cancer on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma: results from a large population-based cohort in China: Erratum.
    Int J Surg. 2026;112:2201.
    

    >> Share

    
    

    
    Int J Urol

41. SOMA T, Tanaka H, Nakamura Y, Numao N, et al
    Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study).
    Int J Urol. 2026;33:e70329.
    

    >> Share

    
    
42. ZAHIR M, Moghadam FS, Ladi-Seyedian SS, Ghoreifi A, et al
    Can Urinary Diversion Type Affect Postoperative Complications Following Radical Cystectomy in Female Patients?
    Int J Urol. 2026;33:e70330.
    

    >> Share

    
    
43. FUJITA N
    Editorial Comments to "Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guerin (BCG) Therapy in BCG-Naive or -Unresponsive Non-Muscle-Invasive Bladder Cancer".
    Int J Urol. 2026;33:e70358.
    

    >> Share

    
    

    
    J Physiol Pharmacol

44. STROJNY Z, Kanikowska A, Sikora W, Lewandowska M, et al
    First look at evaluation of serum angiopoietin-like 4 levels in bladder cancer: A pilot study.
    J Physiol Pharmacol. 2026;76:673-680.
    

    >> Share

    
    

    
    J Transl Med

45. WENG C, Deng H, Yang Z, Zeng X, et al
    Regulation of drug resistance in bladder urothelial carcinoma by tumor aerobic glycolysis.
    J Transl Med. 2025;24:85.
    

    >> Share

    
    

    
    J Vasc Access

46. MAREI A, Hohls M, Touloumtzidis A, Katoh M, et al
    Metastasis of an urothelial carcinoma as rare cause of an AV-graft dysfunction in a transgender patient.
    J Vasc Access. 2026;27:326-331.
    

    >> Share

    
    

    
    Kaohsiung J Med Sci

47. KUO WT, Pan CC, Liu YW, Chow NH, et al
    Autophagy Plays a Suppressive Role in Bladder Tumor Formation in an Orthotopic Mouse Model and Bladder Cancer Patient Specimens.
    Kaohsiung J Med Sci. 2026 Jan 23:e70179. doi: 10.1002/kjm2.70179.
    

    >> Share

    
    

    
    Langenbecks Arch Surg

48. MOHAMED T, Bani Irshid BA, Elhashamy H, Deameh MG, et al
    Optimal duration of perioperative antibiotics in radical cystectomy and urinary diversion: a systematic review and meta-analysis.
    Langenbecks Arch Surg. 2026;411:58.
    

    >> Share

    
    

    
    MedComm (2020)

49. WU J, Jin S, Bai Q, Wang H, et al
    Noninvasive Early Detection and Recurrence Monitoring for Non-Muscle-Invasive Bladder Cancer via Urine Tumor DNA: A Prospective Clinical Study.
    MedComm (2020). 2026;7:e70592.
    

    >> Share

    
    

    
    Medicine (Baltimore)

50. FAN D, Meng R, Han Y, Zhai Z, et al
    Conservative versus aggressive transurethral resection of bladder cancer for paraureteral bladder cancer: A comparison of postoperative ureteral stricture and cancer recurrence rates.
    Medicine (Baltimore). 2026;105:e47176.
    

    >> Share

    
    

    
    Mod Pathol

51. CHEVILLE JC, Orme JJ, Gupta S, Lucien-Matteoni F, et al
    Defining NECTIN4 Amplification and Protein Expression in Urothelial Carcinoma and Histologic Subtypes.
    Mod Pathol. 2026;39:100928.
    

    >> Share

    
    

    
    Mol Cancer Ther

52. LU L, Cheng H, Liu S, Tao Y, et al
    TAK-901 targeted inhibition of EGFR activates transcription factor FOXO causing cell cycle arrest and apoptosis in bladder cancer.
    Mol Cancer Ther. 2026 Jan 19. doi: 10.1158/1535-7163.MCT-25-0507.
    

    >> Share

    
    

    
    Nat Rev Clin Oncol

53. ST-LAURENT MP, Nikkola J, Tomiyama E, Black PC, et al
    Author Correction: Advances in the management of localized bladder cancers.
    Nat Rev Clin Oncol. 2026 Jan 19. doi: 10.1038/s41571-026-01121.
    

    >> Share

    
    
54. COCA MEMBRIBES S, Szabados B, Powles T
    Towards biomarker-driven therapies for urothelial carcinoma.
    Nat Rev Clin Oncol. 2026;23:92-106.
    

    >> Share

    
    

    
    Nat Rev Urol

55. DYRSKJOT L
    ctDNA-guided treatment decisions in muscle-invasive bladder cancer.
    Nat Rev Urol. 2026 Jan 22. doi: 10.1038/s41585-026-01125.
    

    >> Share

    
    

    
    Nihon Hinyokika Gakkai Zasshi

56. NUMATA Y, Ito H, Tatenuma T, Noguchi G, et al
    [A CASE OF ACUTE EXACERBATION OF INTERSTITIAL PNEUMONIA AFTER ROBOT-ASSISTED TOTAL CYSTECTOMY].
    Nihon Hinyokika Gakkai Zasshi. 2025;116:37-40.
    

    >> Share

    
    
57. KURETAKE K, Minato A, Harada S, Fujimoto N, et al
    [CLINICAL OUTCOMES OF NEUROENDOCRINE CARCINOMA OF THE URINARY BLADDER].
    Nihon Hinyokika Gakkai Zasshi. 2025;116:10-16.
    

    >> Share

    
    
58. YAMADA R, Hayakawa N, Kikuchi E
    [PERIOPERATIVE INCIDENCE OF VENOUS THROMBOEMBOLISM IN BLADDER CANCER PATIENTS TREATED BY OPEN RADICAL CYSTECTOMY].
    Nihon Hinyokika Gakkai Zasshi. 2025;116:1-9.
    

    >> Share

    
    

    
    Oncoimmunology

59. REDDY N, Lau K, Naman J, Lu K, et al
    Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma.
    Oncoimmunology. 2026;15:2611458.
    

    >> Share

    
    

    
    Oncol Rep

60. PAN XW, Li L, Huang Y, Huang H, et al
    [Corrigendum] Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy.
    Oncol Rep. 2026;55:51.
    

    >> Share

    
    

    
    Oncol Ther

61. STUART J, Zhuleku E, Mevius A, Squires P, et al
    Characteristics, Treatment Patterns, and Outcomes of Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Analysis of Health Insurance Claims Data in Germany.
    Oncol Ther. 2026 Jan 20. doi: 10.1007/s40487-025-00413.
    

    >> Share

    
    

    
    Urol Oncol

62. LITT HK, Mamtani R, Chow RD
    Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction.
    Urol Oncol. 2026;44:118.
    

    >> Share

    
    
63. HUSSEIN AA, Klugman Y, Carlson J, Bhat TA, et al
    Does the urinary microbiome reflect the bladder-cancer-associated microbiome? Characterizing the microbiome in urine and cancer tissue in bladder cancer.
    Urol Oncol. 2026;44:110978.
    

    >> Share

    
    
64. HE W, Wen Y, Qin H
    LncRNA NPSR1-AS1 affects the malignant biological behavior of bladder cancer through miR-199a-3p and the clinical value of urine-derived lncRNA NPSR1-AS1.
    Urol Oncol. 2026;44:110980.
    

    >> Share

    
    

    
    Urology

65. TJIAMAN MP, Zaidan MZ, Ausath ZF, Putri AT, et al
    Quality of Life and Postoperative Complications of Single- or Bilateral-stoma Cutaneous Ureterostomy Compared to Ileal Conduit After Radical Cystectomy: A Systematic Review and Meta-analysis.
    Urology. 2026;207:287-292.
    

    >> Share

    
    
66. HEARD JR, Pagano I, Rosser C, Tan WS, et al
    Hematuria Cancer Risk Score in Combination With Oncuria-Detect for Patients Undergoing Evaluation for Hematuria.
    Urology. 2026;207:178-183.
    

    >> Share

    
    

    
    World J Surg Oncol

67. LI Y, Zhou Z, Liu J, Cheng Z, et al
    En bloc versus conventional transurethral resection for non-muscle-invasive bladder cancer: an expanded and updated systematic review and meta-analysis reconciling contemporary evidence on oncological, pathological, and safety outcomes.
    World J Surg Oncol. 2026 Jan 20. doi: 10.1186/s12957-025-04172.
    

    >> Share

    
    

    
    World J Urol

68. LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
    Development and external validation of a nomogram predicting cancer-specific mortality-free survival after trimodal therapy in muscle-invasive bladder cancer.
    World J Urol. 2026;44:111.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share